Friday, July 10, 2026

Drug profile · INN

bedaquiline

bedaquiline (SIRTURO) is an FDA-listed pharmaceutical active ingredient.

EMA: approved Antiinfectives for systemic use (J04) J04AK05
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — bedaquiline
Class
Antiinfectives for systemic use (J04)
Route
Patents
0
Programs
6
Data quality
0.83

Quick answer

bedaquiline (SIRTURO) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN bedaquiline
Brand SIRTURO
Therapeutic class Antiinfectives for systemic use (J04)
ATC code J04AK05

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. APHP230852 Phase 3 · PARItec · Patients diagnosed at the study sites with rifampicinresista
  2. Bedaquiline Phase 3 · BRIGHT MINDS BIOSCIENCES · Multi-drug Resistant Tuberculosis
  3. Bedaquiline (B) Phase 3 · First People's Hospital · Pulmonary Tuberculosis
  4. Bedaquiline (B) Phase 2 · Chinese Academy of · Tuberculosis, Pulmonary
  5. Gates MRI-TBD06-201 Phase 2 · BRIGHT MINDS BIOSCIENCES · Pulmonary Tuberculosis
  6. TMC207TBC1006 Phase 1 · Janssen-Cilag International N.V · Tuberculosis

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is bedaquiline?

bedaquiline (SIRTURO) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for bedaquiline?

SIRTURO is a marketed brand name for bedaquiline. Check FDA Drugs@FDA for the current US label holder and prescribing information.